Proteon signs $550 million option deal with Novartis
This article was originally published in Scrip
Executive Summary
Novartis has agreed to commit more than $550 million to the privately held US biopharmaceutical company Proteon Therapeutics if the firm's only clinical candidate is a success. Novartis has the option to acquire Proteon if its lead compound successfully completes Phase II trials.